JP2002255814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002255814A5 JP2002255814A5 JP2001386850A JP2001386850A JP2002255814A5 JP 2002255814 A5 JP2002255814 A5 JP 2002255814A5 JP 2001386850 A JP2001386850 A JP 2001386850A JP 2001386850 A JP2001386850 A JP 2001386850A JP 2002255814 A5 JP2002255814 A5 JP 2002255814A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tetrahydrothieno
- cyclopropylcarbonyl
- fluorobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002357 endometrial effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000002271 resection Methods 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001386850A JP4874482B2 (ja) | 2000-12-25 | 2001-12-20 | アスピリンを含有する医薬組成物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000392983 | 2000-12-25 | ||
| JP2000-392983 | 2000-12-25 | ||
| JP2000392983 | 2000-12-25 | ||
| JP2001386850A JP4874482B2 (ja) | 2000-12-25 | 2001-12-20 | アスピリンを含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002255814A JP2002255814A (ja) | 2002-09-11 |
| JP2002255814A5 true JP2002255814A5 (enExample) | 2005-05-19 |
| JP4874482B2 JP4874482B2 (ja) | 2012-02-15 |
Family
ID=26606540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001386850A Expired - Lifetime JP4874482B2 (ja) | 2000-12-25 | 2001-12-20 | アスピリンを含有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4874482B2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1893205A4 (en) * | 2005-06-17 | 2010-06-30 | Lilly Co Eli | DOSAGE FOR PRASUGREL |
| KR101503083B1 (ko) | 2006-12-07 | 2015-03-16 | 다이이찌 산쿄 가부시키가이샤 | 고형 제제의 제조 방법 |
| US20100280064A1 (en) * | 2006-12-07 | 2010-11-04 | Tomoyuki Watanabe | Pharmaceutical composition having improved storage stability |
| CA2671975C (en) * | 2006-12-07 | 2013-10-29 | Daiichi Sankyo Company, Limited | Film-coated preparation having improved stability |
| EP2100610A4 (en) * | 2006-12-07 | 2009-12-02 | Daiichi Sankyo Co Ltd | PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE |
| KR101442862B1 (ko) | 2006-12-07 | 2014-09-22 | 다이이찌 산쿄 가부시키가이샤 | 만니톨 또는 유당을 함유하는 고형 제제 |
| CN104800210B (zh) | 2007-04-27 | 2019-08-06 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| CA2761455C (en) * | 2009-05-13 | 2018-06-12 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| JPWO2011065444A1 (ja) * | 2009-11-27 | 2013-04-18 | 学校法人東海大学 | 抗血栓剤 |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
-
2001
- 2001-12-20 JP JP2001386850A patent/JP4874482B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5576328A (en) | Method for the secondary prevention of ischemic events | |
| JP2002255814A5 (enExample) | ||
| ES2214632T3 (es) | Composicion farmaceutica antitrombotica y antiaterogena que comprende un derivado de tienopiridina y un inhibidor de la hmg-coa reductasa. | |
| EP1734041A3 (en) | Platelet ADP receptor inhibitors | |
| RU2003118638A (ru) | Медицинские композиции, содержащие аспирин | |
| CA2703697A1 (en) | Acid addition salts of hydropyridine derivatives | |
| ME00090B (me) | Jedinjenja koja sadrže laktam i njihovi derivati kao inhibitori faktora xa | |
| HK1050008A1 (zh) | 杂双环磺胺剂及以其作为血小板腺苷二磷酸(adp)受体抑制剂 | |
| DK1350511T3 (da) | Medicinsk sammensætning indeholdende aspirin | |
| HUT71470A (en) | Pharmaceutical compositions for increasing thrombomodulin expression containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation | |
| JP2002509164A5 (enExample) | ||
| JP2003246735A5 (enExample) | ||
| WO2000021507A3 (de) | Pharmazeutisch wirksame zusammensetzung | |
| JP4874482B2 (ja) | アスピリンを含有する医薬組成物 | |
| RU2005119970A (ru) | Оптически активное производное дигидропиридина | |
| AU2004277734B2 (en) | Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent | |
| CA2590224A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque | |
| WO2007054451A1 (en) | Use of combinations of nitric oxide-releasing aspirin and aspirin for the treatment of cardiovascular diseases | |
| CA2857953A1 (en) | An extended release formulation of a direct thrombin inhibitor | |
| Czuba | Antithrombotic Agents | |
| KR20050026019A (ko) | 동맥-정맥 이식 부전의 예방 및/또는 치료를 위한키마아제 저해제의 용도 | |
| RU98120160A (ru) | Анти-вич-композиция, содержащая имидазольные производные | |
| HK1093900B (en) | Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent | |
| HK1162927A (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| HK1158496A (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |